CN103768050A - Eryngiolide A在治疗或预防慢性心衰的药物中的应用 - Google Patents
Eryngiolide A在治疗或预防慢性心衰的药物中的应用 Download PDFInfo
- Publication number
- CN103768050A CN103768050A CN201210411845.0A CN201210411845A CN103768050A CN 103768050 A CN103768050 A CN 103768050A CN 201210411845 A CN201210411845 A CN 201210411845A CN 103768050 A CN103768050 A CN 103768050A
- Authority
- CN
- China
- Prior art keywords
- eryngiolide
- heart failure
- chronic heart
- treating
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GHZVTIKGATYJRL-WZRMTEHQSA-N (1R,4S,5R,6S,9R,10R,13S,14R,15S)-4,5,13,14-tetrahydroxy-4,9,13-trimethyl-18-methylidene-7,16-dioxatricyclo[13.3.0.06,10]octadecane-8,17-dione Chemical compound C1C[C@](C)(O)[C@H](O)[C@H]2OC(=O)C(=C)[C@H]2CC[C@](C)(O)[C@H](O)[C@H]2OC(=O)[C@H](C)[C@H]21 GHZVTIKGATYJRL-WZRMTEHQSA-N 0.000 title claims abstract description 52
- 206010007558 Cardiac failure chronic Diseases 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 229940079593 drug Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 5
- 206010007556 Cardiac failure acute Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 229960002918 doxorubicin hydrochloride Drugs 0.000 description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 3
- 244000252132 Pleurotus eryngii Species 0.000 description 3
- 235000001681 Pleurotus eryngii Nutrition 0.000 description 3
- DDTBPAQBQHZRDW-UHFFFAOYSA-N cyclododecane Chemical group C1CCCCCCCCCCC1 DDTBPAQBQHZRDW-UHFFFAOYSA-N 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 150000004141 diterpene derivatives Chemical class 0.000 description 3
- 238000007914 intraventricular administration Methods 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000006193 Pulmonary infarction Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000007575 pulmonary infarction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210411845.0A CN103768050B (zh) | 2012-10-25 | 2012-10-25 | Eryngiolide A在治疗或预防慢性心衰的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210411845.0A CN103768050B (zh) | 2012-10-25 | 2012-10-25 | Eryngiolide A在治疗或预防慢性心衰的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103768050A true CN103768050A (zh) | 2014-05-07 |
CN103768050B CN103768050B (zh) | 2015-08-05 |
Family
ID=50561114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210411845.0A Active CN103768050B (zh) | 2012-10-25 | 2012-10-25 | Eryngiolide A在治疗或预防慢性心衰的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103768050B (zh) |
-
2012
- 2012-10-25 CN CN201210411845.0A patent/CN103768050B/zh active Active
Non-Patent Citations (3)
Title |
---|
LU ZI-MING, ET AL.: "A New Diphenylmethane Derivative from Uvaria kurizz with Cardiovascular Activity", 《CHINESE JOURNAL OF NATURAL MEDICINES》 * |
SHAO-JUAN WANG, ET AL.: "Eryngiolide A, a Cytotoxic Macrocyclic Diterpenoid with an Unusual Cyclododecane Core Skeleton Produced by the Edible Mushroom Pleurotus eryngii", 《ORGANIC LETTERS》 * |
孙建波,等: "食用菌及其营养保健功效", 《中国食物与营养》 * |
Also Published As
Publication number | Publication date |
---|---|
CN103768050B (zh) | 2015-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105412101A (zh) | Virosaines A在制备治疗或预防慢性心衰药物中的应用 | |
CN103768050B (zh) | Eryngiolide A在治疗或预防慢性心衰的药物中的应用 | |
CN103585148B (zh) | Nitrosporeusines A在治疗或预防慢性心衰药物中的应用 | |
CN103393698B (zh) | Chukrasone A在制备治疗或预防慢性心衰的药物中的应用 | |
CN103356686B (zh) | Houttuynoid B在制备治疗或预防慢性心衰的药物中的应用 | |
CN103356671B (zh) | Houttuynoid C在制备治疗或预防慢性心衰的药物中的应用 | |
CN103372000B (zh) | Chukrasone B在制备治疗或预防慢性心衰的药物中的应用 | |
CN103356673B (zh) | Houttuynoid A在制备治疗或预防慢性心衰的药物中的应用 | |
CN103610672B (zh) | Hippolachnin A在治疗或预防慢性心衰药物中的应用 | |
CN103599106B (zh) | Caesanines D在制备治疗或预防慢性心衰药物中的应用 | |
CN103356570A (zh) | Sarcaboside B在治疗或预防慢性心衰的药物中的应用 | |
CN103550225B (zh) | Phyllanthoid A在制备治疗或预防慢性心衰药物中的应用 | |
CN102988347A (zh) | Aphanamixoid A在制备治疗或预防慢性心衰的药物中的应用 | |
CN103356548A (zh) | Sarcaboside A在治疗或预防慢性心衰的药物中的应用 | |
CN103381180A (zh) | Houttuynoid E在治疗或预防慢性心衰的药物中的应用 | |
CN103479621A (zh) | Neonectrolide A在制备治疗或预防慢性心衰药物中的应用 | |
CN103316028A (zh) | Polyflavanostilbene A在制备治疗或预防慢性心衰药物中的应用 | |
CN103356670A (zh) | Houttuynoid D在治疗或预防慢性心衰的药物中的应用 | |
CN103263421A (zh) | Myriberine A在制备治疗或预防慢性心衰药物中的应用 | |
CN105287452A (zh) | Periconianone A在制备治疗或预防慢性心衰药物中的应用 | |
CN104997766A (zh) | 一种治疗或预防慢性心衰药物及其应用 | |
CN103372007B (zh) | Chukrasone B在制备治疗或预防急性心衰的药物中的应用 | |
CN103463006A (zh) | Racemosins A在制备治疗或预防慢性心衰药物中的应用 | |
CN105395543A (zh) | Verrulactone C在制备治疗或预防慢性心衰药物中的应用 | |
CN102872031A (zh) | Gypensapogenin B在治疗或预防慢性心衰的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Wu Junhua Inventor after: Li Rongrong Inventor after: Wang Zhongxia Inventor after: Huang Rong Inventor after: Gong Xia Inventor after: Feng Yi Inventor before: Huang Rong Inventor before: Gong Xia Inventor before: Feng Yi Inventor before: Wu Junhua |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: HUANG RONG GONG XIA FENG YI WU JUNHUA TO: WU JUNHUA LI RONGRONG WANG ZHONGXIA HUANG RONG GONG XIA FENG YI |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |